Propanc Biopharma, Inc.: Form 10-Q for the period ended Dec 31, 2012
Filed with the SEC on Feb 20, 2013 and accepted by EDGAR at Feb 19, 2013, 17:34 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2012-10-01 to 2012-12-31 | $1.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2012-07-01 to 2012-12-31 | $1.7k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2012-10-01 to 2012-12-31 | −$446.9k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2012-07-01 to 2012-12-31 | −$942.8k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-10-01 to 2012-12-31 | $1.2k | us-gaap:InterestExpense |
| Interest expense | 6 months2012-07-01 to 2012-12-31 | $2.6k | us-gaap:InterestExpense |
| Income tax | 3 months2012-10-01 to 2012-12-31 | −$61.1k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2012-07-01 to 2012-12-31 | −$61.1k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-10-01 to 2012-12-31 | −$387.8k | us-gaap:NetIncomeLoss |
| Net income | 6 months2012-07-01 to 2012-12-31 | −$880.3k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-10-01 to 2012-12-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2012-07-01 to 2012-12-31 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2012-07-01 to 2012-12-31 | −$77.9k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2012-12-31 | $494 | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-12-31 | $8.3k | us-gaap:AssetsCurrent |
| Total assets | At period end2012-12-31 | $12.3k | us-gaap:Assets |
| Current liabilities | At period end2012-12-31 | $655.5k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2012-12-31 | −$643.2k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001354488-13-000756. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.